New drug wipes out cancer in every single patient that has taken it

New drug wipes out cancer in every single patient that has taken it
Diabetes Drug Leads To Significant Weight Loss in Those With Obesity, Study ...

A new trial drug has wiped out cancer in every single patient that took it.

The study was conducted with 18 rectal cancer patients at Memorial Sloan Kettering Cancer Center in Manhattan, New York, and had a 100 per cent success rate, as stated in a paper published in the New England Journal of Medicine.

In conversation with the New York Times, Dr. Luis A. Diaz Jr, the author of the paper, said the following: “I believe this is the first time this has happened in the history of cancer.”

The drug, which was sponsored by the drug company GlaxoSmithKline, is called dostarlimab.

It was administered to each patient every three weeks for a total of six months.

The participants in the study had colon cancer and were given alternative healing methods, such as chemotherapy or a difficult surgery that could potentially result in bowel or urinary dysfunction.

Sign upto our new free Indy100 weekly newsletter

Some patients were required to use a colostomy bag due to treatment, the Times said.

Towards the end of the drug trial, the patients didn’t face the heartache of potentially damaging treatment when they showed no signs of a tumor after receiving an MRI, biopsy and rectal examination.

“There were a lot of happy tears,” Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center, told the outlet.

Alongside not needing any additional treatment to quell the disease, there were no instances of recurring cancers in the patients during their follow-up appointments from six to 25 months after the trial’s conclusion.

Despite the results being “small but compelling,” Dr Hanna K Sanoff of the University of North Carolina’s Lineberger Comprehensive Cancer Center, who was not affiliated with the study, said it isn’t transparent if the patients are cured.

“Very little is known about the duration of time needed to find out whether a complete clinical response to dostarlimab equates to cure,” Sanoff penned in an editorial accompanying the paper.

Dr. Kimmie Ng, who is a colorectal cancer expert at Harvard Medical School, also noted that the results would need to be repeated despite how “remarkable” it was.

It still serves as hopeful news for patients.

Sascha Roth, a participant in the trial, also said she had plans to move to Manhattan for chemotherapy and radiation treatment ahead of the study’s start.

And then she received golden news from her doctors: The trial was fruitful and she was cancer-free.

“I told my family,” she said. “They didn’t believe me.”

And two years later, it was reported that she did not have a trace of cancer.

Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

The Conversation (0)